Clinical trials: Non-small Cell Lung Cancer Stage IV
Non-Small Cell Lung Cancer (NSCLC)
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum…
- Trial name
- NCT05920356
- Testing
- Sotorasib, Pembrolizumab
- Where
- 424 sites in United States, Argentina and 36 more
- Volunteers
- 750 people
- Sponsor
- Amgen
Non Small Cell Lung Cancer
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
This is a Phase 3, randomized, open-label, comparative, multicenter, international study for NSCLC patients whose tumor tissue exhibits ROS1 fusion positivity (i.e., ROS1+) and who have not previously received an ROS1-targeted…
- Trial name
- NCT06564324
- Testing
- Taletrectinib, Crizotinib
- Where
- 29 sites in China
- Volunteers
- 194 people
- Sponsor
- Nuvation Bio Inc.
NSCLC Stage IV, NSCLC, Stage III
To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC
Primary Objectives: To evaluate the Quality of Life (QoL) score of adding oral Oligo Fucoidan to platinum-based chemotherapy in comparison with placebo in subjects with Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT03130829
- Testing
- Oligo Fucoidan
- Where
- 3 sites in Taiwan
- Sponsor
- Hi-Q Marine Biotech International, Ltd.
NSCLC Stage IIIB~IV
A Randomized, Placebo Controlled Study to Evaluate the Safety and Potential Efficacy of MS-20 in Combination with Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
MS-20 was approved as the first oral cancer adjuvant new drug indicated for ameliorating fatigue and appetite loss associated with cancer chemotherapy via reshaping human gut ecosystem and restoring immunity.
- Trial name
- NCT04909034
- Testing
- MS-20
- Where
- 7 sites in Taiwan
- Volunteers
- 15 people
- Sponsor
- Microbio Co Ltd
Carcinoma, Non-Small-Cell Lung
Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to test whether SU011248 has activity and is safe in patients with metastatic non-small cell lung cancer (NSCLC) who have failed a platinum-containing regimen and docetaxel.
- Trial name
- NCT00092001
- Testing
- Sunitinib
- Where
- 14 sites in United States, Italy and 1 more
- Volunteers
- 111 people
- Sponsor
- Pfizer
Carcinoma, Non-Squamous Non-Small Cell Lung
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This randomized Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin+nab-paclitaxel…
- Trial name
- IMpower130 (NCT02367781)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Carboplatin, Nab-Paclitaxel
- Where
- 132 sites in United States, Belgium and 6 more
- Volunteers
- 723 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer (NSCLC)
A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
This is a Phase II, open-label, multi-centre study to determine the safety of a fixed dose of Durvalumab (MEDI4736) (1500 mg) every 4 weeks [q4w] in participants with unresectable Stage III Non-Small Cell Lung Cancer (NSCLC), who…
- Trial name
- NCT03693300
- Testing
- Durvalumab
- Where
- 28 sites in United States, France and 4 more
- Volunteers
- 117 people
- Sponsor
- AstraZeneca
Non-Small-Cell Lung Cancer
A Study of Induction and Maintenance Treatment of Advanced or Metastatic Non Squamous Non-Small Cell Lung Cancer
This study will estimate the response rate in patients with advanced or metastatic non-squamous Non-Small Cell Lung Cancer. Patients who don't progress after 4 to 6 cycles of induction treatment with pemetrexed, cisplatin and…
- Trial name
- NCT00867009
- Testing
- Pemetrexed, Cisplatin, Cetuximab
- Where
- 24 sites in Austria, Germany and 4 more
- Volunteers
- 113 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Cancer
A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer
This study is a single-arm, open-label, multicenter phase II clinical trial aimed at evaluating the efficacy, safety, and pharmacokinetics of SHR-1826 in treating locally advanced or metastatic non-small cell lung cancer .
- Trial name
- NCT07489716
- Testing
- SHR-1826
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Non-Small Cell Lung Cancer
The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy
The purpose of study is to evaluate the safety, pharmacokinetics and anti-tumor effects of CKD-702 as a monotherapy and to determine the Recommended Phase 2 Dose(RP2D) in patients with advanced or metastatic non-small cell lung…
- Trial name
- CKD-702 (NCT04667975)
- Testing
- CKD-702
- Where
- South Korea
- Volunteers
- 74 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Non-Small Cell Lung Cancer, c-MET
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung.
- Trial name
- NCT06568939
- Testing
- Telisotuzumab Vedotin
- Where
- 83 sites in United States, Brazil and 5 more
- Volunteers
- 150 people
- Sponsor
- AbbVie
Non Small Cell Lung Cancer
FHND9041 Versus Afatinib for Non-small Cell Lung Cancer
The goal of this clinical trial is to evaluate the effectiveness and safety of FHND9041 compared to afatinib as first-line treatments for epidermal growth factor receptor mutation-positive (EGFRm+) locally advanced or metastatic…
- Trial name
- FHND9041 (NCT06759857)
- Testing
- FHND9041, Afatinib
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative
This is a phase Ib, multi-center, open label study evaluating the safety and efficacy of CT053PTSA in combination with gefitinib in patients with EGFR mutation, T790M negative NSCLC who have progressed after EGFR TKI treatment.
- Trial name
- NCT03758287
- Testing
- CT053PTSA, Gefitinib
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
NSCLC (advanced Non-small Cell Lung Cancer), Stage IV Lung Cancer
Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer
The combination of chemotherapy and immunotherapy shows promising results in terms of overall survival (OS) and progression-free survival (PFS) for the treatment of first-line stage IV non-small cell lung cancer (NSCLC) patients…
- Trial name
- NCT06896890
- Testing
- CIS-DPI
- Where
- 15 sites in Belgium, France and 1 more
- Volunteers
- 32 people
- Sponsor
- Inhatarget Therapeutics
Lung Neoplasms, Carcinoma
Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer
The purpose of the study is to determine if U.S. manufactured Cetuximab can be safely used for the treatment of Non-Small Cell Lung Cancer in combination with Cisplatin and Vinorelbine.
- Conditions
- Lung Neoplasms, Carcinoma, Cancer of the Lung, Non-Small-Cell Lung Carcinoma
- Trial name
- NCT01109524
- Testing
- Cetuximab, Cisplatin, Vinorelbine
- Where
- 22 sites in United States, Canada and 1 more
- Volunteers
- 72 people
- Sponsor
- Eli Lilly and Company
Non Small Cell Lung Carcinoma
SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients
The purpose of this study is to evaluate ORR (Objective Response Rate) of gefitinib as a second-line therapy for NSCLC patients based on RECIST (Response Evaluation Criteria in Solid Tumors Group) and check up ORR difference by…
- Trial name
- SELINE (NCT00608868)
- Testing
- Gefitinib
- Where
- South Korea
- Volunteers
- 156 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.
This multi-center, open label Phase II/III clinical study is performed in patients with locally advanced/metastatic NSCLC progressed on prior EGFR-TKI treatment or with non TKI-sensitizing mutation or patients with EGFR exon20ins…
- Trial name
- NCT05020769
- Testing
- SI-B001, Osimertinib
- Where
- 3 sites in China
- Volunteers
- 14 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV
Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer
This is a Phase I, open label multicentre study of selumetinib administered orally in combination with first line chemotherapy regimens to patients with advanced/metastatic NSCLC.
- Trial name
- SELECT-3 (NCT01809210)
- Testing
- selumetinib, gemcitabine, cisplatin
- Where
- 4 sites in United Kingdom
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy
This study involves treatment with KD019 or erlotinib in patients with Non-small cell lung cancer (NSCLC) who have progressed after first- or second- line chemotherapy.
- Trial name
- NCT01487174
- Testing
- KD019, Erlotinib
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Kadmon Corporation, LLC
Non-small Cell Lung Cancer
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD9008 versus platinum-based doublet chemotherapy in participants with locally advanced or metastatic NSCLC with EGFR Exon20ins…
- Trial name
- NCT05668988
- Testing
- sunvozertinib, Pemetrexed+carboplatin
- Where
- 154 sites in United States, Argentina and 13 more
- Volunteers
- 324 people
- Sponsor
- Dizal Pharmaceuticals